Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study: The Determination of the Maximum Tolerable Dosage of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury

NCT01619280 is registered in ClinicalTrials.gov with Mount Sinai Hospital, Canada as lead sponsor.

NCT NCT01619280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01619280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study: The Determination of the Maximum Tolerable Dosage of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury
Lead sponsor
Mount Sinai Hospital, Canada
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2012
Completion date
June 30, 2013
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury, acute respiratory distress syndrome, hypoxia, respiratory failure, sodium nitroprusside